Howard J Eisen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7731198/publications.pdf

Version: 2024-02-01

45 papers

3,427 citations

567281 15 h-index 302126 39 g-index

48 all docs 48 docs citations

48 times ranked

3608 citing authors

#	Article	IF	CITATIONS
1	The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. Journal of Heart and Lung Transplantation, 2010, 29, 914-956.	0.6	1,385
2	Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients. New England Journal of Medicine, 2003, 349, 847-858.	27.0	1,104
3	Three-Year Results of a Randomized, Double-Blind, Controlled Trial of Mycophenolate Mofetil Versus Azathioprine in Cardiac Transplant Recipients. Journal of Heart and Lung Transplantation, 2005, 24, 517-525.	0.6	237
4	Cardiac Allograft Vasculopathy by Intravascular Ultrasound in HeartÂTransplantÂPatients. JACC: Heart Failure, 2013, 1, 389-399.	4.1	110
5	Prevention of Acute Rejection and Allograft Vasculopathy by Everolimus in Cardiac Transplants Recipients: A 24-Month Analysis. Journal of Heart and Lung Transplantation, 2007, 26, 584-592.	0.6	107
6	Temporal Trends of De Novo Malignancy Development After Heart Transplantation. Journal of the American College of Cardiology, 2018, 71, 40-49.	2.8	70
7	Accelerated Allograft Vasculopathy With Rituximab After Cardiac Transplantation. Journal of the American College of Cardiology, 2019, 74, 36-51.	2.8	37
8	New French heart allocation system: Comparison with Eurotransplant and US allocation systems. American Journal of Transplantation, 2020, 20, 1236-1243.	4.7	37
9	Left Ventricular Assist Devices (LVADS): History, Clinical Application and Complications. Korean Circulation Journal, 2019, 49, 568.	1.9	36
10	Long-term cardiovascular risk in transplantationâ€"insights from the use of everolimus in heart transplantation. Nephrology Dialysis Transplantation, 2006, 21, iii9-iii13.	0.7	33
11	Geographic Variation in Heart Failure Mortality and Its Association With Hypertension, Diabetes, and Behavioral-Related Risk Factors in 1,723 Counties of the United States. Frontiers in Public Health, 2018, 6, 132.	2.7	27
12	Discovery of non-HLA antibodies associated with cardiac allograft rejection and development and validation of a non-HLA antigen multiplex panel: From bench to bedside. American Journal of Transplantation, 2020, 20, 2768-2780.	4.7	26
13	Skeletal myoblast transplantation: no MAGIC bullet for ischemic cardiomyopathy. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 520-521.	3.3	18
14	Genetics of Dilated Cardiomyopathy. Current Cardiology Reports, 2018, 20, 121.	2.9	18
15	Frailty in heart transplantation: Report from the heart workgroup of a consensus conference on frailty. American Journal of Transplantation, 2021, 21, 636-644.	4.7	16
16	Prophylactic use of the implantable cardioverter-defibrillator and its effect on the long-term survival, cardiovascular and sudden cardiac death in nonischemic cardiomyopathy patients—a systematic review and meta-analysis. Heart Failure Reviews, 2018, 23, 181-190.	3.9	15
17	Reduction in postpercutaneous coronary intervention angina in addition to gastrointestinal events in patients on combined proton pump inhibitors and dual antiplatelet therapy: a systematic review and meta-analysis. European Journal of Gastroenterology and Hepatology, 2018, 30, 847-853.	1.6	15
18	Readmission rate after ultrafiltration in acute decompensated heart failure: a systematic review and meta-analysis. Heart Failure Reviews, 2017, 22, 685-698.	3.9	14

#	Article	IF	CITATIONS
19	Immunosuppression on the Horizon. Heart Failure Clinics, 2007, 3, 43-49.	2.1	13
20	Burden of Cardiovascular Disease among Multi-Racial and Ethnic Populations in the United States: an Update from the National Health Interview Surveys. Frontiers in Cardiovascular Medicine, 2014, 1, 8.	2.4	10
21	Assessment of pre-operative psychosocial function among people receiving left ventricular assist devices: A national survey of US LVAD programs. Heart and Lung: Journal of Acute and Critical Care, 2019, 48, 302-307.	1.6	10
22	Immunosuppression-state-of-the-art. Current Opinion in Organ Transplantation, 2014, 19, 500-507.	1.6	9
23	Pharmacologic Management for Heart Failure and Emerging Therapies. Current Cardiology Reports, 2017, 19, 94.	2.9	9
24	The Return of the mTOR Inhibitors. Journal of the American College of Cardiology, 2018, 71, 651-653.	2.8	9
25	Meta-Analysis Comparing Outcomes and Need for Renal Replacement Therapy of Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement. American Journal of Cardiology, 2018, 122, 468-476.	1.6	9
26	MICRONUTRIENTS, INFLAMMATION AND CONGESTIVE HEART FAILURE AMONG THE ELDERLY: NUTRITIONAL PERSPECTIVES ON PRIMARY PREVENTION AND CLINICAL TREATMENT. Clinical and Experimental Pharmacology and Physiology, 2007, 34, S14-S16.	1.9	8
27	The Implication of Cardiac Injury Score on In-hospital Mortality of Coronavirus Disease 2019. Journal of Korean Medical Science, 2020, 35, e349.	2.5	8
28	Dietary sugar intake and risk of Alzheimer's disease in older women. Nutritional Neuroscience, 2022, 25, 2302-2313.	3.1	7
29	Delayed aneurysmal complication of bicuspid aortic valve disease after heart transplantation. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, e185-e186.	0.8	6
30	Burden of Uncontrolled Hyperglycemia and Its Association with Patients Characteristics and Socioeconomic Status in Philadelphia, USA. Health Equity, 2020, 4, 525-532.	1.9	5
31	Use of Proliferation Signal Inhibitors in Cardiac Transplantation. Current Transplantation Reports, 2014, 1, 273-281.	2.0	3
32	Pediatric Heart Transplant Recipients and Cardiac Allograft Vasculopathy. Journal of the American College of Cardiology, 2015, 66, 558-560.	2.8	3
33	Ethical Considerations in the Long-Term Ventricular Assist Device Patient. Current Heart Failure Reports, 2017, 14, 7-12.	3.3	2
34	Reduced Stroke After Transcatheter Patent Foramen Ovale Closure: A Systematic Review and Meta-analysis. American Journal of the Medical Sciences, 2018, 356, 103-113.	1.1	2
35	CAVEAT mTOR: You've heard about the benefits of using mTOR inhibitors, here are some of the risks. American Journal of Transplantation, 2021, 21, 449-450.	4.7	2
36	Glutathione S-Transferase Pi-1: A Novel Approach to Mitigating Adverse Cardiac Remodeling After Myocardial Infarction. Journal of Cardiac Failure, 2014, 20, 146-147.	1.7	1

#	Article	IF	CITATIONS
37	Angiotensin-Converting Enzyme Inhibitors for Cardiac Allograft Vasculopathy After Heart Transplantation â^—. Journal of the American College of Cardiology, 2017, 69, 2842-2844.	2.8	1
38	mTOR inhibitors vs calcineurin inhibitors: A Catchâ€22â€"preventing nephrotoxicity or acute allograft rejection after heart transplantation. American Journal of Transplantation, 2019, 19, 2967-2968.	4.7	1
39	What can post market registries tell us about the use of cardiac resynchronization therapy?. Current Heart Failure Reports, 2007, 4, 39-42.	3.3	O
40	Improvements in Dutch heart transplant patient outcomes: lessons for the future. Transplant International, 2015, 28, 960-961.	1.6	0
41	Novel, More Accurate Assessments of Renal Function in Heart Transplant Patients: Commentary on â€~Chronic kidney disease after heart transplantation: a single-centre retrospective study at SkÁ¥ne University Hospital in Lund 1988-2010'. Transplant International, 2016, 29, 527-528.	1.6	0
42	Reply from the authors: Pseudoaneurysm after heart transplantationâ€"Did bicuspid aortopathy contribute?. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, e128-e129.	0.8	0
43	Primum non Nocere. Transplantation, 2021, Publish Ahead of Print, .	1.0	O
44	Novel Immunosuppression in Solid Organ Transplantation. Handbook of Experimental Pharmacology, 2022, , $1.$	1.8	0
45	Something evil this way comes: Proteomic profiling identifies CLEC4C expression as a novel biomarker of primary graft dysfunction after heart transplantation. Journal of Heart and Lung Transplantation, 2022, 41, 269-270.	0.6	0